Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DGP-114
- Development stage
- Preclinical
- Lead developer
- Deargen
01
Overview
**DGP-114** is an investigational preclinical oncology program from Deargen for **ovarian cancer**. Based on Deargen's pipeline, it is listed in the company's 4D Program at the **Target ID** stage, indicating that the candidate remains in early discovery and that its specific molecular target, mechanism of action, modality, formulation, and route of administration have **not been publicly disclosed**. No clinical development, brand name, or manufacturing details were identified from the available company pipeline information.
- Other names
- DGP-114-Deargen-Ovarian CancerDGP114-Deargen-Ovarian CancerDGP 114-Deargen-Ovarian Cancer
Beyond the preview
Go deeper on DGP-114.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DGP-114.